Legato Capital Management LLC Has $569,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Legato Capital Management LLC boosted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 56.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,454 shares of the company’s stock after acquiring an additional 4,831 shares during the quarter. Legato Capital Management LLC’s holdings in Vera Therapeutics were worth $569,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after purchasing an additional 350 shares during the period. KBC Group NV lifted its holdings in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares during the period. AlphaCentric Advisors LLC bought a new stake in shares of Vera Therapeutics in the 3rd quarter valued at about $332,000. SG Americas Securities LLC increased its stake in shares of Vera Therapeutics by 117.5% in the third quarter. SG Americas Securities LLC now owns 9,354 shares of the company’s stock valued at $413,000 after buying an additional 5,053 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. raised its position in shares of Vera Therapeutics by 109.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock worth $416,000 after acquiring an additional 4,914 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wedbush upped their target price on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Finally, Guggenheim boosted their price objective on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Monday, October 28th. One research analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics currently has an average rating of “Buy” and an average price target of $65.44.

Insider Activity

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 52,500 shares of company stock worth $2,305,625 over the last quarter. 21.70% of the stock is currently owned by corporate insiders.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $27.46 on Friday. The business has a 50-day simple moving average of $38.91 and a 200 day simple moving average of $40.85. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -10.52 and a beta of 1.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a one year low of $25.99 and a one year high of $51.61.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.